JP2016529505A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529505A5
JP2016529505A5 JP2016537268A JP2016537268A JP2016529505A5 JP 2016529505 A5 JP2016529505 A5 JP 2016529505A5 JP 2016537268 A JP2016537268 A JP 2016537268A JP 2016537268 A JP2016537268 A JP 2016537268A JP 2016529505 A5 JP2016529505 A5 JP 2016529505A5
Authority
JP
Japan
Prior art keywords
patient
biomarker
level
statin
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016537268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529505A (ja
JP6625535B2 (ja
Filing date
Publication date
Priority claimed from EP13181687.8A external-priority patent/EP2843414B1/en
Application filed filed Critical
Publication of JP2016529505A publication Critical patent/JP2016529505A/ja
Publication of JP2016529505A5 publication Critical patent/JP2016529505A5/ja
Priority to JP2019214467A priority Critical patent/JP6934508B2/ja
Application granted granted Critical
Publication of JP6625535B2 publication Critical patent/JP6625535B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016537268A 2013-08-26 2014-08-26 心不全におけるスタチン治療階層化のためのマーカー Expired - Fee Related JP6625535B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019214467A JP6934508B2 (ja) 2013-08-26 2019-11-27 心不全におけるスタチン治療階層化のためのマーカー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13181687.8A EP2843414B1 (en) 2013-08-26 2013-08-26 Marker for statin treatment stratification in heart failure
EP13181687.8 2013-08-26
PCT/EP2014/068090 WO2015028469A2 (en) 2013-08-26 2014-08-26 Marker for statin treatment stratification in heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019214467A Division JP6934508B2 (ja) 2013-08-26 2019-11-27 心不全におけるスタチン治療階層化のためのマーカー

Publications (3)

Publication Number Publication Date
JP2016529505A JP2016529505A (ja) 2016-09-23
JP2016529505A5 true JP2016529505A5 (enExample) 2017-10-05
JP6625535B2 JP6625535B2 (ja) 2019-12-25

Family

ID=49029008

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016537268A Expired - Fee Related JP6625535B2 (ja) 2013-08-26 2014-08-26 心不全におけるスタチン治療階層化のためのマーカー
JP2019214467A Expired - Fee Related JP6934508B2 (ja) 2013-08-26 2019-11-27 心不全におけるスタチン治療階層化のためのマーカー
JP2021134720A Ceased JP2021185371A (ja) 2013-08-26 2021-08-20 心不全におけるスタチン治療階層化のためのマーカー

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019214467A Expired - Fee Related JP6934508B2 (ja) 2013-08-26 2019-11-27 心不全におけるスタチン治療階層化のためのマーカー
JP2021134720A Ceased JP2021185371A (ja) 2013-08-26 2021-08-20 心不全におけるスタチン治療階層化のためのマーカー

Country Status (6)

Country Link
US (3) US10234464B2 (enExample)
EP (2) EP2843414B1 (enExample)
JP (3) JP6625535B2 (enExample)
CN (2) CN105659095B (enExample)
CA (1) CA2920066A1 (enExample)
WO (1) WO2015028469A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN106018789A (zh) * 2016-08-03 2016-10-12 北京德奥平生物技术有限公司 一种st2定量检测方法及试剂盒
WO2018167447A1 (en) 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US11942219B1 (en) * 2017-09-25 2024-03-26 Cerner Innovation, Inc. Determining a cardiovascular ischemic event and decision support tool
EP3899035B1 (en) * 2018-12-20 2025-04-16 F. Hoffmann-La Roche AG Detection of target nucleic acid by solid-phase molography
CN110361544A (zh) * 2019-07-29 2019-10-22 清华大学深圳研究生院 P1np检测试纸、p1np检测试剂盒和检测方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5695761A (en) 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
US6414219B1 (en) 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
ATE348164T1 (de) 1999-05-17 2007-01-15 Bioph Biotech Entw Pharm Gmbh Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
DE50309809D1 (de) 2002-11-16 2008-06-19 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
EP1929295A4 (en) * 2005-08-30 2010-03-17 Biosite Inc USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
WO2007026214A1 (en) 2005-08-31 2007-03-08 Inverness Medical Switzerland Gmbh Predicting responses to drugs or drug candidates
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
EP1884777A1 (en) * 2006-08-04 2008-02-06 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on GDF-15
WO2008015254A2 (en) 2006-08-04 2008-02-07 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
EP2498095A3 (en) * 2007-01-25 2012-11-28 Roche Diagniostics GmbH Use of IGFBP-7 in the assessment of heart failure
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
JP2011501112A (ja) * 2007-10-10 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 心筋梗塞のモニタリング及びその治療のための手段及び方法
CA2703979A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic ether and thioether derivatives and methods of use thereof
CA2710035C (en) * 2007-12-21 2018-01-16 Mcmaster University Method for assessing risk of heart failure
CA2711221C (en) * 2007-12-31 2017-02-28 Emory University Triarylmethane analogs and their use in treating cancers
WO2009137006A2 (en) * 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
JP2011523044A (ja) * 2008-05-15 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー 拡張型心筋症の区別のための及び特異的治療とその結果の基礎としてのマルチマーカーパネル
WO2009144307A1 (en) * 2008-05-29 2009-12-03 F. Hoffmann-La Roche Ag MEANS AND METHODS FOR IDENTIFYING A SUBJECT BEING SUSCEPTIBLE TO A CARDIAC THERAPY BASED ON DETERMINATION OF A CARDIAC TROPONIN, sCD40L AND C-REACTIVE PROTEIN
CN106370857A (zh) * 2008-10-21 2017-02-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
BRPI0920069A8 (pt) 2008-10-30 2017-10-03 Centre De Rech Public De La Sante Biomarcadores
US20120157378A1 (en) * 2008-11-14 2012-06-21 Simin Liu Methods and Compositions for Predicting a Subject's Susceptibility To and Risk of Developing Type 2 Diabetes
EP2425245B1 (en) * 2009-04-27 2016-10-05 Roche Diagnostics GmbH Use of endostatin as a marker of heart failure
WO2011064358A1 (en) * 2009-11-27 2011-06-03 Roche Diagnostics Gmbh Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction
KR20130040844A (ko) * 2010-03-29 2013-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 약학적으로 유발된 전이유전자 제거 시스템
WO2012003475A1 (en) * 2010-07-02 2012-01-05 Bg Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
EP2367006A1 (en) * 2010-08-24 2011-09-21 Roche Diagnostics GmbH PLGF-based means and methods for diagnosing cardiac causes in acute inflammation
WO2012028713A1 (en) * 2010-09-02 2012-03-08 Roche Diagnostics Gmbh Method for diagnosing and monitoring the cardiac pathophysiological state in a subject undergoing or having undergone percutaneous coronary intervention (pci)
US20120219943A1 (en) * 2011-02-03 2012-08-30 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure

Similar Documents

Publication Publication Date Title
JP6416974B2 (ja) 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
Gumbau et al. A prospective study on inflammatory parameters in obese patients after sleeve gastrectomy
RU2012147597A (ru) Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания
JP2014521089A5 (enExample)
Ostroukhova et al. The effect of statin therapy on allergic patients with asthma
WO2007011746A3 (en) Highly sensitive immunoassays and antibodies for detection of blood factor viii
WO2018026969A3 (en) Plazomicin antibodies and methods of use
Bocci et al. Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity
RU2367430C1 (ru) Способ прогноза эффективности лечения ревматоидного артрита симвастатином
Nishiyama et al. Sarcopenia may influence the prognosis in advanced thyroid cancer patients treated with molecular targeted therapy
Kingren et al. Determination of Burn Size in Mouse Models of Burn Injury: A Scoping Review of Studies Leveraging Scald and Contact Burns
Brunelli et al. Pleural pressure immediately after pulmonary lobectomy: single versus double chest tubes for suction
JP2015503106A5 (enExample)
Fernández-Díaz et al. AB0197 Subclinical intersticial lung disease in early rheumatoid arthritis
Rapoport et al. Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer
Marques et al. AB0367 Influence of Comorbidities on the Functional Capacity and Mobility of Individuals with Rheumatoid Arthritis: A Cross-Sectional Study
Gulacan Tekin et al. Mean Platelet Volume in Patients With Dilated Cardiomyopathy: Does it have a Role in Left Ventricular Thrombus Formation?
JP2020500543A5 (enExample)
Vinod et al. Evaluation of serum osteocalcin in patients with rheumatoid arthritis
Mochida et al. AB0368 Analyses for Recurrences of Hallux Valgus Deformity after Implant Surgery in Rheumatoid Arthritis
Yadav et al. Postoperative Acute Respiratory Distress Syndrome: A Prospective Biomarker Analysis
Gurevich et al. P371 RELATIONSHIP BETWEEN CD59 POSITIVE PERIPHERAL MONONUCLEAR CELLS AND HDL-CHOLESTEROL LEVELS IN PATIENTS WITH PROGRESSING ATHEROSCLEROSIS
Jahantigh et al. P368 PROFILING OF MICRORNAS FOLLOWING VASCULAR INJURY IN ApoE−/− MICE
Fóris et al. P369 HYPERCHOLESTEROLEMIA (HC) ABROGATES THE CONCENTRATION-DEPENDENT BIPHASIC EFFECT OF ANGIOTENSIN (ANG II) ON ENDOGENOUS CHOLESTEROL SYNTHESIS IN HUMAN MONOCYTES
de la Cuesta et al. P372 PROTEOMIC ANALYSIS OF HUMAN ATHEROSCLEROTIC CORONARY INTIMA REVEALS NOVEL POTENTIAL BIOMARKERS IN HUMAN ATHEROSCLEROSIS